The FDA on October 18, 2016 modified the indication for TARCEVA® for treatment of Non Small Cell Lung Cancer, to limit use to patients whose tumors have specific Epidermal Growth Factor Receptor (EGFR) mutations. TARCEVA® is a product of Astellas Pharm Global Development Inc.
Bottom Ad
Advertisement
Subscribe
